Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.

Hou, Mengmeng; Liu, Minchao; Yu, Hongyue; Kou, Yufang; Jia, Jia; Zhou, Qiaoyu; Zhang, Fan; Zhao, Dongyuan et al. · Nano Lett · 2024

basic_science · Level V

Where this comes from

Abstract

Despite its effectiveness in eliminating cancer cells, ferroptosis is hindered by the high natural antioxidant glutathione (GSH) levels in the tumor microenvironment. Herein, we developed a spatially asymmetric nanoparticle, Fe<sub>3</sub>O<sub>4</sub>@DMS&PDA@MnO<sub>2</sub>-SRF, for enhanced ferroptosis. It consists of two subunits: Fe<sub>3</sub>O<sub>4</sub> nanoparticles coated with dendritic mesoporous silica (DMS) and PDA@MnO<sub>2</sub> (PDA: polydopamine) loaded with sorafenib (SRF). The spatial isolation of the Fe<sub>3</sub>O<sub>4</sub>@DMS and PDA@MnO<sub>2</sub>-SRF subunits enhances the synergistic effect between the GSH-scavengers and ferroptosis-related components. First, the increased exposure of the Fe<sub>3</sub>O<sub>4</sub> subunit enhances the Fenton reaction, leading to increased production of reactive oxygen species. Furthermore, the PDA@MnO<sub>2</sub>-SRF subunit effectively depletes GSH, thereby inducing ferroptosis by the inactivation of glutathione-dependent peroxidases 4. Moreover, the SRF blocks Xc<sup>-</sup> transport in tumor cells, augmenting GSH depletion capabilities. The dual GSH depletion of the Fe<sub>3</sub>O<sub>4</sub>@DMS&PDA@MnO<sub>2</sub>-SRF significantly weakens the antioxidative system, boosting the chemodynamic performance and leading to increased ferroptosis of tumor cells.

Medical subject headings